Dr. John Shen, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
200 Med Plaza, # 365,420,120
Los Angeles, CA 90045
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 432
Licensed in California since 2014, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A128805 (first issued 2014; current) -
Geriatric Medicine (Internal Medicine) Physician
CA license A128805 (first issued 2014; current) -
Internal Medicine Physician
CA license A128805 (first issued 2014; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 432
- Services billed
- 57,359
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 8,670 | 11 |
| Injection, denosumab, 1 mg | 6,060 | 26 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 760 | 92 |
| Injection, dexamethasone sodium phosphate, 1 mg | 625 | 24 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 574 | 17 |
| Established patient office or other outpatient visit, 30-39 minutes | 539 | 239 |
| Injection, ondansetron hydrochloride, per 1 mg | 496 | 18 |
| Established patient office or other outpatient visit, 40-54 minutes | 458 | 193 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 279 | 136 |
| Infusion, normal saline solution, 250 cc | 222 | 73 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Abiraterone Acetate | 205 |
| Erleada (apalutamide) | 177 |
| Prednisone Other prescribers in Los Angeles, CA | 145 |
| Nubeqa (darolutamide) | 137 |
| Xtandi (enzalutamide) | 119 |
| Orgovyx (relugolix) | 85 |
| Tamsulosin Hcl Other prescribers in Los Angeles, CA | 46 |
| Potassium Chloride Other prescribers in Los Angeles, CA | 19 |
| Lynparza (olaparib) | 17 |
| Venlafaxine Hcl Er (venlafaxine hcl) Other prescribers in Los Angeles, CA | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 11 payments worth $3,753 in total to this clinician.
| Onmark, Inc. | $3,663 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $90.15 |
| Travel and Lodging | $2,205 |
|---|---|
| Food and Beverage | $1,529 |
| Gift | $19.74 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Onmark, Inc. Nov 3, 2025 | Travel and Lodging travel to Irving, TX | $1,787 |
| Onmark, Inc. Nov 3, 2025 | Travel and Lodging travel to Irving, TX | $418 |
| Onmark, Inc. Nov 3, 2025 | Gift | $19.74 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $165,760 in research payments for these studies, mostly to the institutions running them.
- A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Pros…
AstraZeneca UK Limited - A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Eli Lilly and Company · Active, not recruiting · NCT05288166 - A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Pa…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.